• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

Psychedelic Decriminalization Update

Jason Najum by Jason Najum
January 21, 2022
in Law & Politics
Reading Time: 2 mins read
A A
Psychedelic Decriminalization Update

2021 saw some serious progress towards the decriminalization of psychedelics. We had California getting close to the finish line with a historic bill; Seattle becoming the largest US city to decrim drugs; Detroit decriminalising psychedelics; and the city of Toronto voting to request a decrim exemption from the federal government.

2022 seems to be continuing this trend. There’s been a steady stream of initiatives by advocates and local politicians, all pushing for institutional and legislative changes to restriction on psychedelics.

Here are some recent highlights:

Washington State Psilocybin Bill

Following in its neighbor Oregon footsteps, a group of bipartisan lawmakers in Washington State have introduced legislation to legalize the use of psilocybin in certain situations. The Psilocybin Wellness and Opportunity Act would allow individuals to consume products containing psilocybin if under the care of a trained and state-licensed psilocybin service administrator.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Thrilled to announce SB5660 The WA #Psilocybin Services Wellness & Opportunity Act, which I had the privilege to help draft. Thanks to Sen Salomon @SenLizLovelett @DecrimNatureSEA & John Rapp
@HarrisBricken#psychedelic #health #law @UNHLaw @PetrieFlom
https://t.co/p5p7ei9BME pic.twitter.com/cqWlC79LY4

— Mason Marks, MD, JD (@MasonMarksMD) January 5, 2022

Continue on your trip...

Psylutions and the DEA

US Congress Adds Psychedelics Studies to Defense Bill

Enveric Granted US Patent for Psilocybin Derivatives

Utah Bill to Look at Mental Illness & Psychotherapy Drugs

Purchase Fast Lasix

Bill, H.B. 167, was sponsored by Republican Representative Brady Brammer this month.

The bill wants to create a Mental Illness Psychotherapy Drug Task Force to research and make recommendations on controlled drugs currently available for legal therapeutic use. The goal is to find alternatives for treating symptoms of mental illnesses.

If the bill passes it would be a major step in getting lawmakers to see the benefits of therapies like psychedelics.

 

Virginia Politicians Wants to Reduce Penalties for Psychedelics

The state of Virginia is getting a decrim push with two bills that will remove criminal penalties for the possession of psychedelics.

HB 898 proposes to decriminalize the “possession of certain naturally occurring hallucinogens or psychoactive substances”. The other Senate bill focuses more on psilocybin, making the possession a minor civil penalty, with a small fine instead of criminal charges

https://www.instagram.com/p/CY70qi-uLr1/

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Top Federal Drug Official is Bullish on Psychedelic Reform

The National Institute on Drug Abuse (NIDA), a government agency, seems to be taking psychedelics seriously. NIDA Director Nora Volkow said the “train has left the station” on psychedelics and that there’s “an incredible opportunity to also modify the way that we are doing things.”

These topics were raised at a recent psychedelics workshop hosted by the NIDA and the National Institute of Mental Health (NIMH).

Don't miss out on the @NIDAnews, @NIAAAnews, & @NIMHgov-sponsored virtual Workshop on Psychedelics as Therapeutics: Gaps, Challenges, and Opportunities, Jan. 12‒13, 2022. Learn more and register: https://t.co/S1zttkoYXq pic.twitter.com/C2Qrk6FN9a

— NIDAnews (@NIDAnews) January 10, 2022

Two government agencies hosting a workshop on psychedelics as therapeutics? The time they are a changin’…

Tags: Decriminalization
Jason Najum

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Next Post

News You Might Have Missed: Jan 24th, 2022

Please login to join discussion

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.